Editorial: Bringing GERD management up to PAR-2

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

Proton pump inhibitors (PPIs) are extremely effective for mucosal healing of reflux esophagitis, but less so for relieving the symptom of heartburn. PPIs block the secretion of gastric acid, the caustic effects of which have been assumed to be the primary culprit in the pathogenesis of reflux esophagitis. However, mounting data suggest that reflux-stimulated, immune-mediated mechanisms may underlie the development of esophagitis in patients with gastroesophageal reflux disease (GERD). Thus, the future of GERD therapy, particularly for patients who are refractory to PPIs, may be the targeting of proteins such as proteinase-activated receptor-2, which have central roles in the generation of immune-mediated esophageal mucosal damage and in eliciting the symptom of heartburn.

Original languageEnglish (US)
Pages (from-to)1944-1946
Number of pages3
JournalAmerican Journal of Gastroenterology
Volume105
Issue number9
DOIs
StatePublished - Sep 1 2010

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Editorial: Bringing GERD management up to PAR-2'. Together they form a unique fingerprint.

  • Cite this